September 3, 2019
Comments Off on Gaithersburg-based Viela Bio files for $150M IPO
Viela Bio, the MedImmune spinout that has attracted more than $300 million in venture capital, filed for a $150 million initial public offering last week.
Tagged with: Viela Bio
Read More »
August 20, 2018
Comments Off on Viela Bio begins clinical trials months after $250M spinoff
One of Maryland’s best-funded biotech companies took a milestone first step Monday, announcing it has begun clinical trials of a medication it is developing. Gaithersburg-based Viela Bio was spun out of MedImmune, a subsidiary of AstraZeneca, last month with $250 million in ...
Tagged with: clinical study medimmune Viela Bio
Read More »
April 11, 2018
Comments Off on Md. continues venture capital momentum with $405 million in Q1
Maryland companies continued last year’s strong performance in receiving venture capital investments, sparked by the large Viela Bio deal, according to the quarterly MoneyTree Report from PricewaterhouseCoopers LLP and CB Insights. With more than $405 million invested last quarter, Maryland ...
Tagged with: MoneyTree Report PricewaterhouseCoopers venture capital Viela Bio
Read More »
February 28, 2018
Comments Off on With $250M from investors, Viela Bio out on its own
MedImmune spun out Viela Bio as an independent biotechnology company with $250 million in Series A financing and six potential medicines, the companies announced Wednesday. Viela Bio will be based in Gaithersburg and will focus on inflammation and autoimmunity biologics, ...
Tagged with: AstraZeneca medimmune Viela Bio
Read More »
Maryland Daily Record Maryland's trusted source for business and legal news
